Functional relevance of soluble TNF-α, transmembrane TNF-α and TNF-signal transduction in gastrointestinal diseases with special reference to inflammatory bowel diseases

Zeitschrift fur Gastroenterologie

Volumn 40, Issue 8, 2002, Pages 587-600

  Holtmann, M H ^a   Schutz M ^a   Galle, P R ^a   Neurath, M F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Gastrointestinal disorders; Inflammatory bowel disease; Signal transduction; TNF

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL MODEL; COLITIS; ENTERITIS; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; INFLAMMATION; LIVER TOXICITY; PANCREATITIS; PATHOGENESIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; VIRUS HEPATITIS;

ANTIBODIES, MONOCLONAL; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 1; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036672560     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33418     Document Type: Review

References (167)

1. The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation
2. Himan pro-tumor necrosis factor is a homotrimer
3. An evolutionary and functional approach to the TNF receptor/ligand family
4. A new cluster of genes within the human major histocompatibility complex
5. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells
6. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha
7. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
8. Crystallization of trimeric recombinant human tumor necrosis factor (cachectin)
9. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway
10. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators
11. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies
12. Molecular cloning and expression of a receptor for human tumor necrosis factor
13. Chromosomal location of the human tumor necrosis factor receptor genes
14. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13
15. Identification of a 60-kD tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses
16. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
17. Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: Requirement of the TNF receptor-associated factor-2 binding site
18. Continuous autotropic signaling by membrane-expressed tumor necrosis factor
19. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling
20. Tumor necrosis factor receptor-associated factors (TRAFs) - A family of adapter proteins that regulates life and death
21. FADD a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
22. The TNF receptor 1-associated protein TRADD signals cell death and NF- kappa B activation
23. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
24. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity
25. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation
26. Chimeric tumor necrosis factor receptors with constitutive signaling activity
27. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor
28. Anatomy of TRAF2. Distinct domains for nuclear factor-kappaB activation and association with tumor necrosis factor signaling proteins
29. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
30. Role of NF-kappaB in immune and inflammatory responses in the gut
31. The anti-inflammatory agents aspirin and salicylate inhibit the activity of l(kappa)B kinase-beta
32. NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-lAP1 and c-lAP2 to suppress caspase-8 activation
33. l-TRAF is a novel TRAF-interacting protein that regulates TRAF-mediated signal transduction
34. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein
35. The tumor necrosis factor-inducible zinc finger protein A20 interacts with TRAF1/TRAF2 and inhibits NF-kappaB activation
36. The p80 TNF receptor-associated kinase (p80TRAK) associates with residues 354-397 of the p80 cytoplasmic domain: Similarity to casein kinase
37. Identification of a protein kinase associated with the cytoplasmic domain of the p60 tumor necrosis factor receptor
38. A novel domain within the 55 kd TNF receptor signals cell death
39. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain
40. RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death
41. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex
42. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis
43. FLICE, a novel FADD- homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/ APO-1) death-inducing signaling complex
44. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40
45. Stimulus-dependent synergism of the antiapoptotic tumor necrosis factor receptor-associated factor 2 (TRAF2) and nuclear factor kappaB pathways
46. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice
47. Tumor necrosis factor induces rapid production of 1′2′diacylglycerol by a phosphatidylcholine-specific phospholipase C
48. Renaturation and tumor necrosis factor-alpha stimulation of a 97-kDa ceramide-activated protein kinase
49. Signal transduction via the MAP kinases: Proceed at your own RSK
50. Tumor necrosis factor: A pleiotropic cytokine and therapeutic target
51. An endotoxin-induced serum factor that causes necrosis of tumors
52. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes
53. Characterization of tumor necrosis factor-deficient mice
54. Tumor necrosis factor, other cytokines and disease
55. Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response
56. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor
57. Leukocyte-endothelial adhesion molecules
58. Neutrophil migration across monolayers of cytokine-prestimulated endothelial cells: A role for platelet-activating factor and IL-8
59. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells
60. Pathogenesis of disseminated intravascular coagulation in sepsis
61. Fibrinolytic response to tumor necrosis factor in healthy subjects
62. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia
63. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome
64. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia
65. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock
66. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo
67. Disseminated melanoma, preclinical therapeutic studies, clinical trials, and patient treatment
68. Modulation of endothelial cell hemostatic properties by TNF: Insight into the role endothelium in the host response to inflammatory stimuli
69. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas
70. Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages
71. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
72. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
73. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
74. Tumor necrosis factor receptor-1 signaling is required for differentiation of follicular dendritic cells, germinal center formation, and full antibody responses
75. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
76. Crucial role of 55-kilodalton TNF receptor in TNF-induced adhesion molecule expression and leukocyte organ infiltration
77. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice
78. Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria
79. A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R
80. Pattern of soluble TNF receptors I and II in sepsis
81. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection
82. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with acute pancreatitis
83. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity
84. Soluble receptors for tumour necrosis factor: A putative marker of disease progression in HIV infection
85. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis
86. Cytokine gene expression in Helicobacter pylori associated antral gastritis
87. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with Helicobacter pylori associated gastritis
88. Cytokine gene expression in the gastric mucosa: Its role in chronic gastritis
89. Tumor necrosis factor alpha and interleukin lbeta up-regulate gastric mucosal Fas antigen expression in Helicobacter pylori infection
90. Involvement of the CD95 (APO-1/Fas) receptor and ligand system in Helicobacter pylori-induced gastric epithelial apoptosis
91. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: Role of tumour necrosis factor alpha
92. Induction of endogenous tumor necrosis factor-alpha: Suppression of centrally stimulated gastric motility
93. The presence of tumor necrosis factor-alpha and its antibody in the sera of cachexic patients with gastrointestinal cancer
94. Gene expression for tumor necrosis factor alpha and its production in gastric cancer patients
95. Unraveling function in the TNF ligand and receptor families
96. Tissue-specific cytokine production during experimental acute pancreatitis. A probable mechanism for distant organ dysfunction
97. Cytokine production by CAPAN-1 and CAPAN-2 cell lines
98. Pancreatic acinar cells produce, release, and respond to tumor necrosis factor-alpha. Role in regulating cell death and pancreatitis
99. Trypsin stimulates production of cytokines from peritoneal macrophages in vitro and in vivo
100. NF-kappaB/Rel activation in cerulein pancreatitis
101. Tumor necrosis factor alpha signaling pathway and apoptosis in pancreatic beta cells
102. Tumor necrosis factor-alpha-activated cell death pathways in NIT-1 insulinoma cells and primary pancreatic beta cells
103. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection
104. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C
105. Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection
106. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis
107. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors
108. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis
109. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation
110. Regulation of Fas-mediated apoptosis by NF-kappaB activity in human hepatocyte derived cell lines
111. Activation of nuclear factor kappaB in hepatitis C virus infection: Implications for pathogenesis and hepatocarcinogenesis
112. Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis
113. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis
114. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis
115. Primary biliary cirrhosis shows association with genetic polymorphism of tumour necrosis factor alpha promoter region
116. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis
117. T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lymphotoxin, tumor necrosis factor and interferon-gamma upon mitogen stimulation
118. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity
119. Antibodies to tumor necrosis factor alfa attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat
120. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease
121. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
122. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease
123. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease
124. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease
125. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease
126. Suppression of T cell-mediated injury in human gut by interleukin 10: Role of matrix metalloproteinases
127. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
128. Enhancing Lamina propria Th1 cell responses with interleukin 12 produces severe tissue injury
129. Experimental models of inflammatory bowel disease
130. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice
131. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice
132. Interleukin-10-deficient mice develop chronic enterocolitis
133. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice
134. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in crohn disease and experimental colitis in vivo
135. Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (RAG)2(-/-) mice upon transfer of CD4(+)CD45RB(hi) T cells
136. Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice
137. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
138. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease
139. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
140. Induction of remission by interferon-alpha in patients with chronic active ulcerative colitis
141. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
142. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571
143. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
144. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
145. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
146. Infliximab induces apoptosis in monocytes from patients with chronic active crohn's disease by using a caspase-dependent pathway
147. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
148. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
149. Infliximab for the treatment of fistulas in patients with Crohn's disease
150. The relationship between infliximab treatment and lymphoma in Crohn's disease
151. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
152. Etanercept. Soluble tumor necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNF 001, Enbrel
153. Etanercept for active crohn's disease: A randomized, double-blind, placebo-controlled trial
154. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease
155. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease
156. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease
157. Adenosine kinase inhibitor GP515 improves experimental colitis in mice
158. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice
159. Protein kinase C-dependent effects on leukocyte migration of thalidomide
160. Thalidomide is an inhibitor of angiogenesis
161. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
162. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
163. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
164. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures